Table 2.
Clinical factors associated with PFS and OS in MCL patients on COX analysis
| Variable | Groups | Univariate COX analysis | Multivariate COX analysis | ||
|---|---|---|---|---|---|
| OS HR (95% CI P value) | PFS HR (95% CI P value) | OS HR (95% CI P value) | PFS HR (95% CI P value) | ||
| Age | > 60 vs. ≤ 60 | 0.50 (0.16–1.55, p = 0.230) | 0.70 (0.28–1.71, p = 0.429) | ||
| Ann Arbor | I/II vs. III/IV | 4.11 (1.27–13.30, p = 0.018) | 3.10 (1.18–8.13, p = 0.022) | ||
| LDH | Normal vs. abnormal | 3.60 (1.33–9.76, p = 0.012) | 4.97 (2.00–12.37, p < 0.001) | 2.98 (1.03–8.64, p = 0.044) | 5.00 (1.79–13.96, p = 0.002) |
| Extranodal sites | < 2 vs. ≥ 2 | 2.28 (0.85–6.12, p = 0.101) | 3.14 (1.34–7.35, p = 0.008) | ||
| ECOG | 0–1 vs. ≥ 2 | 4.17 (0.90–19.26, p = 0.068) | 4.65 (1.32–16.38, p = 0.017) | ||
| B symptom | Without vs. with | 6.52 (2.42–17.58, p < 0.001) | 4.47 (1.91–10.48, p < 0.001) | 5.80 (2.08–16.21, p = 0.001) | 4.38 (1.67–11.46, p = 0.003) |
| Laterality | Unilateral vs. bilateral | 2.44 (0.78–7.56, p = 0.124) | 3.26 (1.27–8.39, p = 0.014) | 7.55 (2.56–22.32, p < 0.001) | |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; LDH = lactate dehydrogenase